Amneal Pharmaceuticals, Inc. AMRX Income Statement
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| $722.52M+3.9% | $814.32M+11.5% | $784.51M+11.7% | $724.51M+3.2% | $695.42M+5.5% | ||
| $402.41M-8.4% | $517.13M+10.6% | $510.54M+17.9% | $438.26M-3.0% | $439.53M+4.4% | ||
| $320.11M+25.1% | $297.19M+13.1% | $273.97M+1.6% | $286.25M+14.5% | $255.89M+7.5% | ||
| 44.3%+7.5pp | 36.5%+0.5pp | 34.9%-3.5pp | 39.5%+3.9pp | 36.8%+0.7pp | ||
| $38.38M-4.1% | $34.82M-35.8% | $63.35M+3.7% | $47.96M+33.0% | $40.04M+1.9% | ||
| $138.86M+17.4% | $146.46M+13.8% | $137.82M+16.1% | $124.27M+6.7% | $118.29M+5.1% | ||
| $5.15M— | —— | —— | —— | $0— | ||
| $6.94M+35.5% | $1K— | $117K-88.6% | $0— | $5.12M+5,222% | ||
| $141.77M+41.3% | $112.03M+47.8% | $70.34M-20.8% | $111.37M+16.7% | $100.35M+1,034% | ||
| 19.6%+5.2pp | 13.8%+3.4pp | 9%-3.7pp | 15.4%+1.8pp | 14.4%+16.1pp | ||
| -$53.36M+6.3% | -$56.24M+8.8% | -$62.81M+4.1% | -$65.1M+0.9% | -$56.94M+13.3% | ||
| -$61.6M+2.0% | -$56.8M+37.7% | -$75.57M-3.0% | -$59.66M+20.5% | -$62.86M+3.0% | ||
| -$3.51M— | —— | -$31.37M— | —— | $0— | ||
| $80.18M+114% | $55.24M+461% | -$5.22M-134% | $51.71M+153% | $37.49M+150% | ||
| $2.18M-83.1% | $5.66M+4.4% | -$23.36M-737% | $16.1M+345% | $12.87M+109% | ||
| $62.26M+411% | $35.08M+213% | $2.37M+1,619% | $22.42M+274% | $12.2M+113% | ||
| 8.6%+6.9pp | 4.3%+8.6pp | 0.3%+0.3pp | 3.1%+2.2pp | 1.8%+15.7pp | ||
| $0.19+375% | $0.11+210% | $0.01— | $0.07+250% | $0.04+113% | ||
| $0.20+400% | $0.11+210% | $0.01— | $0.07+250% | $0.04+113% | ||
| 328.9M+1.5% | 324.8M+5.1% | 324.8M+4.9% | 322.4M+1.1% | 324M+5.4% | ||
| 316M+1.6% | 313.4M+1.4% | 314.2M+1.5% | 313.7M+1.5% | 311.1M+1.2% | ||
| -$694K— | $0+100% | $0-100% | $390K+156% | $0+100% | ||
| $2.33M+122% | -$12.29M+48.7% | $20.81M+284% | -$4.42M+67.1% | -$10.69M-449% | ||
| -$53.36M+6.3% | -$56.24M+8.8% | -$62.81M+4.1% | -$65.1M+0.9% | -$56.94M+13.3% | ||
| -$7.8M-284% | —— | -$3.43M-251% | $8.26M+3,251% | $4.25M+455% | ||
| $1.54M-12.7% | $1.41M-23.8% | $2.44M+23.9% | $2.02M+93.6% | $1.77M+79.6% | ||
| $742K+43.2% | $13.17M+506% | $1.24M+4.8% | $1.6M-63.2% | $518K-87.3% | ||
| $6.94M+35.5% | $1K— | $117K-88.6% | $0— | $5.12M+5,222% | ||
| $722.52M+3.9% | $814.32M+11.5% | $784.51M+11.7% | $724.51M+3.2% | $695.42M+5.5% | ||
| $141.77M+41.3% | $112.03M+47.8% | $70.34M-20.8% | $111.37M+16.7% | $100.35M+1,034% | ||
| $141.77M+41.3% | $112.03M+47.8% | $70.34M-20.8% | $111.37M+16.7% | $100.35M+1,034% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What is Amneal Pharmaceuticals, Inc.'s revenue?
- Amneal Pharmaceuticals, Inc. (AMRX) generated $3.0B in revenue over the trailing twelve months, up 7.6% year over year.
- Is Amneal Pharmaceuticals, Inc. profitable?
- Amneal Pharmaceuticals, Inc. reported $122.1M in net income over the trailing twelve months, a 4.0% net margin.
- What are Amneal Pharmaceuticals, Inc.'s profit margins?
- Gross margin is 38.7% and operating margin is 14.3%, with a 4.0% net margin.
- What is Amneal Pharmaceuticals, Inc.'s earnings per share?
- Amneal Pharmaceuticals, Inc.'s diluted EPS over the trailing twelve months is $0.38.
- Where does Amneal Pharmaceuticals, Inc.'s income statement data come from?
- Every line is extracted from Amneal Pharmaceuticals, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
